Skip to main content

VibroSense establish sales in Germany

Following the completion of the survey of the German market, VibroSense will begin the next step in establishing sales in Germany. The plan includes introducing the company's product VibroSense Meter II at selected reference clinics.

Germany is an important export market that is expected to be very valuable in the long term for the Diabetes Foot Screening application. As part of the establishment, VibroSense will participate in Germany's largest diabetes conference, Diabetes Congress 2022, in Berlin on 25-28 May this year.

The step into Germany has been preceded by preparatory work where more than 160 diabetes clinics have been contacted and they will be further processed during the spring and summer.

“The German market means a new great opportunity for VibroSense. We have carried out thorough analysis and have a clear picture of the structure of the German diabetes market and its actors. Germany is one of Europe's largest markets and this will be the start of a long-term investment by VibroSense,” says Hans Wallin, CEO of VibroSense Dynamics AB.

About Diabetes in Germany *
There are currently more than 8.5 million people with diabetes in Germany. More than 600,000 new cases are added each year. If the trend continues, 12.3 million people in Germany are expected to have diabetes by 2040.

About 32,000 children and adolescents under the age of 19 have type 1 diabetes. Every year, about 3,100 children and adolescents up to the age of 17 develop type 1 diabetes. The proportion of new cases of type 1 diabetes is currently increasing by 3 to 5 percent annually.

The total annual diabetes care costs amount to approximately EUR 21 billion. Two-thirds of the costs are related to the treatment of diabetic complications.

* Source

Hans Wallin, CEO of VibroSense Dynamics AB
Tel: +46 40 88 026

About VibroSense Dynamics AB (publ)
VibroSense Dynamics AB (publ) develops and sells medical technology products and services for diagnostic support for nerve injuries in the hands and feet. The method is based on measuring and quantifying the ability to feel vibrations at several frequencies. The company's customers are diabetes clinics, occupational health care, hospitals, health centers and researchers.

Our vision is that the company's products should be a standard instrument in all neurological examinations to detect early signs of changes in sensation so that patients and their caregivers can put in place preventive measures that prevent, reduce or delay the occurrence of nerve damage in the hands and feet.